Home HomeContact Us
Welcome to BCG Oncology
About Donald L. Lamm, MD About BCG Oncology Frequently Asked Questions Appointment Information Get a Second Opinion Online!
Bladder, prostate and other GU cancers
Symptoms
Treatment and Prevention
Research
Forms
Information for Physicians
Recursos en Espaņol

Meet Dr. Lamm
Experience
Publications
Ask Dr. Lamm
Search:  
Online Consultation

Sign up online for a virtual consultation with Dr. Lamm, a pioneer in the treatment of bladder and other genitourinary cancers.
Pay Online with Your Credit Card!

Printer Friendly

Multivitamin Antioxidants that Fight Cancer
ONCOVITE
Antioxidant
Multivitamins
Dr. Lamm's specially formulated and tested multivitamin tablets deliver a megadose of antioxidants that is beneficial when combined with BCG or other cancer treatment options.

We subscribe to the HONcode principles of the HON Foundation. Click to verify. We subscribe to the HONcode principles.
Verify here.

 

Publications

Dr. Lamm's bibliography includes more than 270 publications. Below is a partial list that represents Dr. Lamm's areas of interest and expertise.

Selected Publications

  1. Lamm DL, Harris SC and Gittes RF: Bacillus Calmette-Guerin and Dinitrochlorobenzene immunotherapy of chemically induced bladder tumors. Invest Urology 14:369, 1977.
  2. Lamm DL, Reichert DF, Radwin HM and Thor DE: Bacillus Calmette-Guerin immunotherapy of the cancer-contaminated wound. J Surg Res 27(1):14-22, 1979.
  3. Lamm DL, Yee GN, Reichert DF and Radwin HM: Levamisole immunotherapy of experimental transitional cell carcinoma. Invest Urol 16(4):286-288, 1979.
  4. Lamm DL, Thor DE, Harris SC, Reyna JA, Stogdill VD and Radwin HM: BCG immunotherapy of superficial bladder cancer. J Urol 124(1):38-40, 1980.
  5. Lamm DL, Reyna JA and Reichert DF: Keyhole-Limpet Hemocyanin and immune ribonucleic acid immunotherapy of murine transitional cell carcinoma. Urol Res 9(5):227-230, 1981.
  6. Lamm DL, Thor DE, Winters WD, Stogdill VD and Radwin HM: BCG immunotherapy of bladder cancer: Inhibition of tumor recurrence and associated immune responses. Cancer 48(1):82-88, 1981.
  7. Lamm DL, Thor DE, Stogdill VD and Radwin HM: Bladder cancer immunotherapy. J Urol 128(5):931-935, 1982.
  8. Lamm DL, Reichert FD, Harris SC and Lucio RM: Immunotherapy of murine transitional cell carcinoma. J Urol 128(5):1104-1108, 1982.
  9. Lamm DL: Bacillus Calmette-Guerin immunotherapy for bladder cancer. J Urol 134(1):40-47, 1985.
  10. Lamm DL: Bacillus Calmette-Guerin immunotherapy. J Urol 138(2): 391-392, 1987.
  11. Lamm DL: BCG in carcinoma in situ and superficial bladder tumors. EORTC Genitourinary Group Monograph 5: Progress and Controversies in Oncological Urology II. Prog Clin Biol Res 269:497-507, 1988.
  12. Lamm DL, Crissman J, Blumenstein B, et al: Adriamycin versus BCG in superficial bladder cancer: A Southwest Oncology Group Study. Prog Clin Biol Res 310(11):263-270, 1989.
  13. Lamm DL, DeHaven JI, Shriver J, Crispen R, Grau D and Sarosdy MF: A randomized prospective comparison of oral versus intravesical and percutaneous Bacillus Calmette-Guerin for superficial bladder cancer. J Urol 144(1):65-67, 1990.
  14. Lamm DL, Riggs DR, DeHaven JI and Bryner RW: Immunotherapy of murine bladder cancer by irradiated tumor vaccine. J Urol 145(1):195-198, 1991.
  15. Lamm DL, DeHaven JI, Shriver J and Sarosdy MF: Prospective randomized comparison of intravesical with percutaneous Bacillus Calmette-Guerin versus intravesical Bacillus Calmette-Guerin in superficial bladder cancer. J Urol 145(4):738-740, 1991.
  16. Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino P, Grossman HB, Stanisic TH, Smith JA, Sullivan, J, Sarosdy, MF, Crissman, JD and Coltman, CA: A randomized trial of intravesical doxorubicin and immunotherapy with Bacille Calmette-Guerin for transitional cell carcinoma of the bladder. New Engl J Med 325(17):1205-1209, 1991
  17. Lamm DL, DeHaven JI, Riggs DR and Ebert RF: Immunotherapy of murine bladder cancer with Keyhole Limpet Hemocyanin (KLH). J Urol 149(3):648-652, 1993.
  18. Lamm DL, DeHaven JI, Riggs DR, Delgra A, and Burrell R: Immunotherapy of Murine Transitional Cell Carcinoma with Immucothel, a Modification of Keyhole Limpet Hemocyanin (KLH). Urol Res 21: 21-33, 1993.
  19. Lamm DL, Riggs DR, Shriver JS, VanGilder PF, Rach JF and DeHaven JI: Megadose vitamins in bladder cancer: a double-blind clinical trial. J Urol 151(1):21-26, 1994.
  20. Lamm DL, Riggs DR, Traynelis CT and Nseyo UO: Apparent failure of current intravesical chemotherapy prophylaxis to influence the long term course of superficial transitional cell carcinoma of the bladder. J Urol 153:1444-50, 1995.
  21. Lamm DL, Blumenstein BA, Crawford ED, Crissman JD, Lowe BA, Smith JA, Sarosdy MF, Schellhammer PF, Sagalowsky AI, Messing EM, Loehrer P, and Grossman, HB: Randomized Intergroup Comparison of Bacillus Calmette-Guerin Immunotherapy and Mitomycin C Chemotherapy PrRophylaxis in Superficial Transitional Cell Carcinoma of the Bladder. A Southwest Oncology Group Study. Urol Oncol 1:119-126, 1995.
  22. Riggs DR, DeHaven JI and Lamm DL: Allium sativum (garlic) Treatment for Murine Transitional Cell Carcinoma. Cancer 79(10):1987-1994, 1997.
  23. Lamm DL: Bladder cancer: twenty years of progress and the challenges that remain. CA Cancer J Clin 48(5): 263-268, 1998
  24. Lamm DL, Riggs DR, Donley MS, White J, Yeater R, and Bryner RW: Bacillus Calmette-Guerin Immunotherapy Significantly Prolongs Survival of Animals with Prostate Cancer. The Prostate Journal 1(4): 190-194, 1999.
  25. Lamm DL and Riggs DR: The potential application of Allium sativum (garlic) for the treatment of bladder cancer. Urol Clin North Am 27(1): 157-162, 2000.
  26. Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Grossman HB, Beck TM, Leimert JT, and Crawford ED: Maintenance bacillus Calmette-Guerin immunoterapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 163(4): 1124-1129, 2000.
  27. Lamm DL: Efficacy and safety of bacille Calmette-Guerin immunotherapy in superficial bladder cancer. Clin Infect Dis. 31 Suppl 3:S86-90, 2000.
  28. Hogan TF, Lamm DL, Ducatman AM. Smoking and renal cell carcinoma. W V Med J. 97(1):32-5, 2001.
  29. Somji S, Sens MA, Lamm DL, Garrett SH, Sens DA: Metallothionein isoform 1 and 2 gene expression in the human bladder: evidence for upregulation of MT-1X mRNA in bladder cancer. Cancer Detect Prev. 25(1):62-75, 2001.
  30. Kamat AM, Lamm DL: Immunotherapy for bladder cancer. Curr Urol Rep. 2(1):62-9, 2001.
  31. Kamat AM, Lamm DL: Chemoprevention of bladder cancer. Urol Clin North Am. 29(1):157-68, 2002.
  32. Lamm DL: Superficial bladder cancer. Curr Treat Options Oncol. 3(5):403-11, 2002.
  33. Sylvester RJ, van der MEIJDEN AP, Lamm DL: Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 168(5):1964-70, 2002.
  34. Simon SD, Ferrigni RG, Novicki DE, Lamm DL, Swanson SS, Andrews PE: Mayo Clinic Scottsdale experience with laparoscopic nephron sparing surgery for renal tumors. J Urol. 169(6):2059-62, 2003.
  35. Kamat AM, Lamm DL: Antitumor activity of common antibiotics against superficial bladder cancer. Urology. 63(3):457-60, 2004.
  36. Simon SD, Castle EP, Ferrigni RG, Lamm DL, Swanson SK, Novicki DE, Andrews PE: Complications of laparoscopic nephrectomy: the Mayo clinic experience. J Urol. 171:1447-50, 2004.
  37. Schenkman E, Lamm DL. Superficial bladder cancer therapy. ScientificWorldJournal. 1 (Suppl):387-99, 2004.

 

 
Home | Meet Dr. Lamm | About Us | Common Questions | Office Visit | e-Consultation
Cancer Information | Symptoms | Treatment & Prevention | Research | Forms | For Physicians

BCG Oncology, PC | 16620 North 40th Street, Suite E | Phoenix, AZ 85032 | (602) 493-6626

Copyright © 2007 BCG Oncology, PC. All rights reserved. Medical content authored by Donald L. Lamm, M.D., unless otherwise noted.
The information available on and through the BCGOncology.com Web site is presented in summary form as a supplement to, and NOT a substitute for, the knowledge, skill, and judgment of qualified physicians and health care professionals. The information on BCGOncology.com has been obtained from sources believed to be accurate and reliable. However, BCG Oncology, PC makes no warranty as to the accuracy, reliability, or completeness of this information. Information accessed on or through BCGOncology.com is neither complete nor exhaustive and does not cover all disabilities, diseases, illnesses, and physical conditions or their management or treatment. Information accessed on and through BCGOncology.com is provided "AS IS" and without warranty, express or implied, including, but not limited to, any implied warranty of merchantability or of fitness for a particular purpose. View our  terms of use for more information. Donald L. Lamm, MD is licensed to practice medicine in the state of Arizona, only.

Site design and development by Alamo Web Pros, www.AlamoWebPros.com.